by kati.sallinen@desentum.fi | May 16, 2025 | News
All three abstracts submitted by Desentum have been accepted for oral presentations at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Glasgow, UK, on Jun 13–16, 2025. Two of the presentations will showcase the...
by kati.sallinen@desentum.fi | Apr 2, 2025 | News
Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well tolerated in birch...
by kati.sallinen@desentum.fi | Jan 31, 2025 | News
Desentum Oy:n (“Yhtiö”) yhtiöjärjestyksen 9 §:n mukaisesti osakkeenomistajille ilmoitetaan, että Exu Capital Oy on myynyt yhteensä 6000 B-osaketta (“Osakkeet”) 2,00 euron osakekohtaiseen hintaan. Osakkeiden siirtymisestä on...
by kati.sallinen@desentum.fi | Jun 10, 2024 | News
Pekka Mattila, CEO of Desentum was conferred as Honorary Doctor at the University of Eastern Finland on Jun 7, 2024. The Faculty of Science, Forestry and Technology stated the following: “In 2011, Pekka Mattila and researchers from the Department of Chemistry at the...
by raikeeoy | Feb 8, 2024 | News
Desentum, a Finnish biopharmaceutical company with its birch pollen allergy vaccine candidate DM-101PX currently being tested in a clinical study in Canada, raised 12 M€ in a funding round arranged by an investment service company Springvest Oyj. Desentum intends to...
by kapu@raikee.fi | Nov 27, 2023 | News
Desentum announces today that DM-101-C-002, a clinical study evaluating safety and tolerability of the investigational birch pollen allergy vaccine DM-101PX, has been fully recruited and the dosing of all cohorts has been started. DM-101-C-002 is a randomised,...
